Adamax Peptide Dosing Guide: Optimal Protocols

Overview

Adamax is a nootropic research peptide in the Semax-family class, designed for cognitive function and neurological support. As an analog of the ACTH 4-7 fragment, it belongs to a family of synthetic peptides developed in Russia for stroke treatment, cognitive enhancement, and neuroprotection. Adamax is not FDA-approved in the United States, and direct clinical evidence for this specific compound is limited. This guide provides an educational overview of Adamax dosing patterns based on related Semax-family research, presented as a text-based dosage chart for discussion with a licensed healthcare provider. You can use our Adamax dosage calculator → to plan protocol schedules and check reconstitution math — for educational purposes only.

What is Adamax?

Adamax, also known as a Semax-family analog, is a nootropic peptide that targets cognitive function and neurological support. The Semax family originates from synthetic analogs of the ACTH 4-7 fragment, extended with Pro-Gly-Pro (PGP) to increase central nervous system stability and activity. The parent compound Semax was developed in Russia and is approved there for stroke treatment, cognitive enhancement, and neuroprotection.

Key characteristics:

• Mechanism: ACTH fragment analog with CNS-targeted activity
• Route: Intranasal or subcutaneous injection
• Legal status: Not FDA-approved — research only
• Specialty: Neurological and cognitive
• Alternate name: Semax-family analog

Semax has poor oral bioavailability, which is why it is administered parenterally — typically as a nasal spray or subcutaneous injection for direct CNS delivery. Adamax follows the same administration principle. To calculate your protocol dosing, see our Adamax dosage calculator → The parent compound Semax has a short plasma half-life of approximately 7 minutes for the active fragment, though CNS effects persist longer.

Adamax dosage chart

There is no established FDA-approved dose for Adamax. The chart below summarizes dosing patterns drawn from related Semax-family research protocols and peptide community discussions. It is intended for educational reference only — not as a personal dosing plan or medical recommendation.

Protocol Phase	Dose Range	Route	Frequency	Duration	Use Case
Standard intranasal	200-600 mcg per day	Intranasal	1-2 doses daily	10-14 days	Cognitive enhancement, focus, neuroprotection
Subcutaneous injection	100-300 mcg per day	SubQ injection	1 dose daily	7-14 days	Sustained CNS delivery, deeper neurological support
Lower-dose exploratory	100-200 mcg per day	Intranasal	1 dose daily	5-10 days	Conservative starting approach, sensitivity assessment
Acute cognitive boost	300-600 mcg single dose	Intranasal	As needed (not daily)	Single use	Short-term focus or study session support
Extended cycle	200-400 mcg per day	Intranasal or SubQ	1-2 doses daily	14-21 days	Extended cognitive protocol, post-stroke research
Cycle break	No dose	N/A	N/A	1-4 weeks off	Recovery period between research cycles

If you want to organize a protocol schedule or check reconstitution math, use our Adamax dosage calculator → — but only as a conversation tool, not a self-treatment plan. Important: These ranges are drawn from research community discussions and related Semax-family protocols, not FDA-approved clinical guidelines. Adamax is not FDA-approved for any therapeutic use.

How Adamax works in the body

Adamax belongs to the Semax family of nootropic peptides. The parent compound Semax is a synthetic heptapeptide analog of the ACTH 4-7 fragment, extended with Pro-Gly-Pro (PGP) to increase CNS stability and activity. This structure allows the peptide to influence cognitive pathways through direct CNS delivery.

Key mechanisms discussed in research literature:

• Neuroprotection: Semax-family peptides have shown neuroprotective effects in animal and Russian clinical studies, particularly after ischemic events
• Cognitive enhancement: Improved attention, memory, and learning capacity reported in Russian clinical trials
• BDNF expression: Semax has been shown to increase brain-derived neurotrophic factor (BDNF) expression, supporting neuronal health
• Monoamine modulation: Influences dopamine and serotonin systems, contributing to mood and focus effects

The short plasma half-life (approximately 7 minutes for the active fragment) means the compound is rapidly cleared from blood, but CNS effects persist longer due to direct neural uptake. This supports divided dosing (1-2 times daily) rather than continuous administration.

Potential benefits discussed in research

Research on Adamax and the Semax family often focuses on several areas:

1. Cognitive enhancement — improved attention, memory consolidation, and learning capacity

2. Neuroprotection — protection of neural tissue after ischemic events or oxidative stress

3. Post-stroke recovery — Semax is approved in Russia for stroke recovery and cognitive rehabilitation

4. Mood and anxiety — some Semax-family peptides show anxiolytic (anti-anxiety) properties

5. ADHD and focus support — research exploring attention deficit and focus applications

However, it is important to note that most robust clinical evidence comes from Russian clinical literature on Semax itself, not Adamax specifically. Direct clinical evidence for Adamax is limited, and the compound is not FDA-approved.

Safety considerations

The safety profile of Adamax is not fully characterized in human studies. Key safety points include:

• Side effects — compound-specific and not fully characterized in human studies; may include nasal irritation (intranasal route), injection site reactions (SubQ route), mild headache, or transient changes in mood
• Short half-life — the active fragment clears rapidly from plasma, which may reduce cumulative toxicity risk but also requires frequent dosing
• No FDA approval — the compound has not undergone FDA review for safety, effectiveness, or quality
• Drug interactions — not well studied; discuss with a healthcare provider if taking CNS-active medications
• Unknown long-term effects — extended or repeated use has not been systematically studied

Before considering any Adamax protocol, discuss with a healthcare provider:

• Complete medical history, especially neurological or psychiatric conditions
• Current medications, particularly CNS-active drugs (antidepressants, stimulants, anti-anxiety)
• Any history of nasal issues (if using intranasal route)
• Pregnancy or lactation status
• The exact product source, concentration, and labeling

Administration and reconstitution

Adamax can be administered via two routes in research settings:

Intranasal (primary research route):

• Delivered as a nasal spray or intranasal drops
• Provides direct CNS delivery bypassing the blood-brain barrier
• Typical concentration: 0.1-1% solution
• Divided into 1-2 doses per day
• Avoid if nasal passages are congested or irritated

Subcutaneous injection (alternative route):

• Reconstitute with bacteriostatic water
• Inject subcutaneously, typically in the abdomen
• Provides more sustained systemic delivery
• Rotate injection sites daily
• After reconstitution, refrigerate and use within the product-specified timeframe. For exact reconstitution math, use our Adamax dosage calculator →

The intranasal route is more commonly discussed in Semax-family research because it provides direct CNS access. The subcutaneous route may be used when intranasal delivery is impractical or when more sustained plasma levels are desired.

Common mistakes with Adamax dosing

1. Treating research doses as therapeutic doses — there is no FDA-approved dose for Adamax. Research community numbers are not clinical guidelines.

2. Assuming more is better — given the short half-life and CNS activity, increasing dose may increase side effect risk without proportional cognitive benefit. The CNS responds to peptide signaling, not just raw quantity.

3. Ignoring route differences — intranasal and subcutaneous administration produce different pharmacokinetic profiles. The intranasal route provides direct CNS access, while SubQ provides more sustained systemic levels. Do not interchange doses between routes without understanding the difference.

4. Stacking without medical supervision — combining Adamax with other nootropics, stimulants, or CNS-active compounds may produce unpredictable interactions.

5. Extended use without breaks — research protocols typically include off-periods. Continuous use without breaks may lead to tolerance or unknown cumulative effects.

The practical takeaway

Adamax is a nootropic research peptide in the Semax family with potential cognitive and neuroprotective applications. However, direct clinical evidence is limited, and the compound is not FDA-approved. The dosing patterns in this guide are drawn from related Semax-family research and community discussions, not FDA-approved clinical trials.

For anyone considering Adamax, the responsible approach is to treat it as a research compound with promising but unverified benefits. Discuss any protocol with a qualified healthcare provider, understand the differences between intranasal and subcutaneous administration, and use dosage charts as educational tools rather than personal prescriptions.

Related Peptides

Frequently Asked Questions

Related Guides